Champions Oncology, Inc.
CSBR
$7.05
-$0.02-0.28%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.46% | -0.47% | -11.76% | 41.77% | 16.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.46% | -0.47% | -11.76% | 41.77% | 16.56% |
| Cost of Revenue | -2.23% | 13.05% | 0.29% | -15.70% | 12.24% |
| Gross Profit | 28.25% | -14.15% | -24.70% | 149.93% | 22.32% |
| SG&A Expenses | 36.59% | 5.21% | 6.54% | -7.83% | -17.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.41% | 13.90% | 1.67% | -14.09% | -5.70% |
| Operating Income | -74.73% | -138.15% | -1,145.12% | 274.58% | 137.44% |
| Income Before Tax | -65.49% | -133.88% | -933.68% | 279.36% | 135.87% |
| Income Tax Expenses | 63.64% | -33.33% | -59.26% | 109.09% | 0.00% |
| Earnings from Continuing Operations | -67.45% | -135.49% | -1,583.49% | 277.67% | 135.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.19% | -133.21% | -1,583.49% | 277.67% | 135.15% |
| EBIT | -74.73% | -138.15% | -1,145.12% | 274.58% | 137.44% |
| EBITDA | -52.08% | -108.38% | -312.56% | 333.64% | 176.89% |
| EPS Basic | -63.81% | -132.71% | -1,567.50% | 276.30% | 134.94% |
| Normalized Basic EPS | -59.41% | -128.38% | -771.68% | 277.98% | 135.64% |
| EPS Diluted | -61.20% | -135.11% | -1,195.15% | 263.16% | 132.59% |
| Normalized Diluted EPS | -60.00% | -129.29% | -771.68% | 269.78% | 134.59% |
| Average Basic Shares Outstanding | 1.46% | 1.43% | 1.18% | 0.79% | 0.72% |
| Average Diluted Shares Outstanding | 3.14% | -1.81% | 1.18% | 5.67% | 3.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |